OMICS International

International Conferences

Meet Inspiring Speakers and Experts at our 3000+ Global Conferenceseries Events with over 1000+ Conferences, 1000+ Symposiums and 1000+ Workshops on Medical, Pharma, Engineering, Science, Technology and Business.

Explore and learn more about Conference Series Ltd: World’s leading Event Organizer

 

Recommended Conferences for Drug Repurposing

Drug Repurposing


As per available reports about 43 relevant Journals, 29 Conferences  are presently dedicated exclusively to Drug repurposing  and about 3,058 articles are being published on Drug repurposing  .

Drug repurposing  is the application of known drugs and compounds to new indications (i.e., new diseases. A huge point of interest of drug repurposing over conventional medication advancement is that since the repositioned medication has officially passed of lethality and different tests, its safety is known and the danger of disappointment for reasons of adverse toxicology are lessened. More than 90% of drug come up short amid improvement, and this is the most huge purpose behind the high expenses of pharmaceutical R&d. Likewise, repurposed drug can sidestep a great part of the early cost and time required to put up a drug for sale to the public. Drug repositioning, Drug repurposing, Drug rescue, Therapeutic Switching are the different wings constituted under Market analysis and Research opportunity which also include other Pharmaceutical research and Marketing is profused  in developed countries like USA, Middle East & Asia Pacific,

OMICS International Organizes 1000+ Global Events Every Year across USA, Europe & Asia with support from 1000 more scientific societies and Publishes 700+ Open access journals which contains over 100000 eminent personalities, reputed scientists as editorial board and organizing committee members. The conference series website will provide you list and details about the conference organize worldwide.

Scope and Importance:

Drug repositioning has already passed a significant number of toxicity and other tests, its safety is known and the risk of failure for reasons of adverse toxicology are reduced. More than 90% of drugs fail during development and this is the most significant reason for the high costs of pharmaceutical R&D. In addition, repurposed drugs can bypass much of the early cost and time needed to bring a drug to market. On the other hand drug repositioning faces some challenges itself since the intellectual property issues surrounding the original drug may be complex and from a commercial point of view it may not always make sense to take such a drug to market.

Drug repurposing has been becoming in importance in the last few years as an expanding number of medication advancement and pharmaceutical organizations see their drug pipelines becoming scarce and understand that many previously promising technologies have failed to deliver as advertised.

Utilizing drug repurposing, pharmaceutical organizations have attained a number victories, for instance Pfizer's Viagra in erectile brokenness and Celgene's thalidomide in severe erythema nodosum leprosum. More diminutive organizations, including Ore Pharmaceuticals, Biovista, Numedicus, Melior Discovery and [SOM Biotech] are additionally performing drug repurposing on an orderly premise. These organizations utilize a mixed methodologies incorporating in silico science and in vivo/in vitro experimentation to evaluate a compound and create and affirm theories concerning its utilization for new evidences. e system lymphoproliferative disorder and familial dysautonomia.

A huge point of interest of drug repurposing over conventional medication advancement is that since the repositioned medication has officially passed a noteworthy number of lethality and different tests, its safety is known and the danger of disappointment for reasons of adverse toxicology are lessened. More than 90% of drug come up short amid improvement, and this is the most huge purpose behind the high expenses of pharmaceutical R&d. Likewise, repurposed drug can sidestep a great part of the early cost and time required to put up a drug for sale to the public. Then again drug repurposing confronts a few difficulties itself since the intellectual property issues encompassing the original drug may be perplexing and from a business perspective it may not always make sense to take such a drug to market.

One notable example of drug repurposing is taking the incomplete mu-opioid receptor agonist buprenorphine - which has been prescribed for control of moderate pain for a decades in low doses as Temgesic 200mcg sublingual tablets, Buprenex 300mcg/ml ampoules - and promoting a high-dosage formulation (Subutex 2 mg and 8 mg) for the intrusion and support of heroin and other opioid addictions, which it has demonstrated extremely helpful for, with in excess of 200,000 individuals in the United States alone on buprenorphine maintenance.

Market Analysis:

Drug repurposing has become a matter of intense interest during the past few years. It is an approach to drug development that calls for reinvestigation of those drugs that did not succeed in advanced clinical trials (for reasons other than safety) for potential use in other therapeutic indications. Pharma Reports focus on drug repositioning in  pharmaceutical R&D—the technologies, the companies, the markets, and the strategic business impacts.

International symposium and workshops

  • 17th International Pharmaceutical Technology Symposium
  • International Conference on Industrial Pharmacy
  • British Pharmacological Society Conference,
    Dec 13-15, 2016, London, UK

List of Best International Conferences:

  1. 8th Pharmaceutics and Novel Drug Delivery Systems Conference
    March 07-09, 2016 Madrid, Spain
  2. Industrial Pharmacy Conference
    April 28-29, 2016 Dubai, UAE
  3. 4th Medicinal Chemistry and Computer Aided Drug Designing Conference
    December 01-03, 2016 Chicago, USA
  4. 2nd Parenterals and Injectables Conference
    October 24-26, 2016 Istanbul, Turkey
  5. 4th Clinical Pharmacy Conference
    Oct 31 - Nov 01, 2016 Las Vegas, USA
  6. 2nd Drug Discovery and Designing Conference
    Oct 31-Nov 02, 2016 Istanbul, Turkey
  7. 4th Neuropharmacology Conference
    September 15-17, 2016 San Antonio, USA
  8. 7th Pharmacovigilance and Clinical Trials Conference
    September 19-21, 2016 Vienna, Austria
  9. 6th Pharmacovigilance Congress
    August 01-03, 2016 Toronto, Canada
  10. 3rd Pharmacology Congress
    August 08-10, 2016 Birmingham, UK
  11. 6th Annual Drug Delivery & Formulation Americas Summit
    April 14-15, 2016 Costa Mesa, CA, US
  12. 18th International Conference on Pharmaceutical Sciences & Pharmacology
    January 21 - 22, 2016, Paris, France
  13. American Society for Clinical Pharmacology & Therapeutics Annual Meeting
    March 9-12, 2016, California, United States
  14. 7th Annual Global Drug Delivery & Formulation Summit
    May 23-25, 2016 Dusseldorf, Germany
  15. Drug Delivery Partnerships 2016 (DDP 2016)
    January 20-22, 2016 Palm Beach Gardens, FL, US
  16. Peptide Drug Design & Delivery Summit
    February 24-25, 2016 San Francisco, CA, US   

Relevant Society and Associations

  • National Pharmacy Association
  • American Association of Pharmaceutical Scientists
  • American College of Clinical Pharmacology
  • Academy of Managed Care Pharmacy
  • American Association of Colleges of Pharmacy
  • American Society for Clinical Pharmacology and Therapeutics
  • American College of Clinical Pharmacy
  • Arkansas State Board of Pharmacy
  • Association of Pharmacy Technicians UK
  • Austrian Pharmaceutical Society
  • Association of Pharmacy Professionals
  • Pharmaceutical Society of Ireland
  • Pharmaceutical Society Of New Zealand
  • Pharmaceutical Association of Mauritius
  • International Pharmaceutical Federation (FIP)
  • European Pharmaceutical Union (EPU)
  • Pharmaceutical Group of the European Union (PGEU)
  • European Association of Employed Community Pharmacists in Europe (EPhEU)
  • Pharmaceutical Society of Australia
  • Canadian Pharmacists Association
  • Danish Association of Pharmaconomists

Companies

  • AstraZeneca
  • Accredo Therapeutics
  • Actelion Pharmaceuticals US, Inc
  • Bayer HealthCare
  • CRITICAL CARE
  • Cané Medical Technology
  • CVS Caremark
  • CuraScript
  • Fairview Specialty Pharmacy
  • Gilead Sciences
  • Vivisol
  • AIM
  • Henry Schein
  • Snap Diagnostics
  • MediLexicon
  • Nicos Group Inc.
  • Bausch & Lomb Instruments
  • JEDMED
  • Miami Medical
  • Image Stream Medical

This page will be updated regularly.

This page was last updated on 11th Sep, 2015

Conferenceseries Destinations

Contact Us

Medical Conferences
Jessie Grace
jessie.grace@conferenceseries.com
1-702-508-5200 Ext:8031, 8041

Pharmaceutical Conferences
Badoni Victor
badoni.victor@conferenceseries.com
1-702-508-5200 Ext:8045, 8047

Immunology & Microbiology Conferences
Walker Smith
walker.smith@conferenceseries.com
1-702-508-5200 Ext:8031

Cancer Conferences
Raul Cliff
raul.cliff@conferenceseries.com
1-702-508-5200 Ext:8039

Nursing and Healthcare Conferences
Jennifer Leny
jennifer.leny@conferenceseries.com
1-702-508-5200 Ext:8044

Diabetes Conferences
Stanley knight
stanley.knight@conferenceseries.com
1-702-508-5200 Ext:8040

Neuroscience Conferences
Sandeep Kumar
sandeep@conferenceseries.com
1-702-508-5200 Ext:8034

Dental Conferences
Raul Cliff
raul.cliff@conferenceseries.com
1-702-508-5200 Ext:8039

Clinical and Biochemistry Conferences
Rohit Casper
rohit.casper@conferenceseries.com
1-702-508-5200 Ext:8033

Biotechnology Conferences
Ravi Vittal
ravi.vittal@conferenceseries.com
1-702-508-5200 Ext:8031, 8037

Material Science Conferences
Lucy Grey
lucygrey@conferenceseries.com
1-702-508-5200 Ext:8035

Genetics & Mol Biology Conferences
Stephen Bruce
stephen.bruce@conferenceseries.com
1-702-508-5200 Ext:8038

Engineering Conferences
Dolly A
dolly@conferenceseries.com
+1-702-508-5200 Ext:8051

Program Enquiries
Symposia/Workshops
Sponsorships
Media Partners | Advertising